title: Increased GFR and renal excretory function by activation of TRPV1 in the isolated perfused kidney.
abstract: To test the hypothesis that activation of the transient receptor potential vanilloid type 1 (TRPV1) channels leads to natriuresis and diuresis via an increase in glomerular filtration rate (GFR), recirculating Krebs-Henseleit buffer added with inulin was perfused in the isolated perfused kidney of male Wistar rat at a constant flow, and perfusion pressures (PPs) were pre-adjusted to three different levels ( approximately 100, approximately 150, and approximately 190mmHg) with phenylephrine. Capsaicin (Cap), a selective TRPV1 agonist, was perfused in the presence or absence of capsazepine (Capz), a selective TRPV1 antagonist, CGRP(8-37), a selective calcitonin gene-related peptide (CGRP) receptor antagonist, or spantide II (Spa), a selective substance P (SP) receptor antagonist. At the higher (150 and 190mmHg) but not baseline (100mmHg) PP levels, Cap at 10microM significantly decreased PP and increased GFR, urine flow rate (UFR) and Na+ excretion (UNaV). At the highest (190mmHg) PP level, Cap (2, 10, 30microM) dose-dependently decreased PP and increased GFR, UFR, UNaV, and the release of CGRP and SP. Capz or CGRP(8-37) combined with Spa fully blocked the effect of Cap on PP, GFR, UFR, UNaV, and the release of CGRP and SP. In conclusion, activation of TRPV1 in the isolated kidney decreases renal PP and increases GFR and water/sodium excretion possibly via simultaneous activation of CGRP and SP receptors upon their enhanced release, suggesting that TRPV1 plays a key role in modulating renal hemodynamics and excretory function.
authors.affiliation: Department of Medicine, Neuroscience Program, and Cell and Molecular Biology Program, Michigan State University, East Lansing, MI 48824, USA.
authors.forename: Jianping
authors.initials: J
authors.lastname: Li
authors.forename: Donna H
authors.initials: DH
authors.lastname: Wang
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D015740:Calcitonin Gene-Related Peptide / Q000494:pharmacology; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D002211:Capsaicin / Q000031:analogs & derivatives / Q000494:pharmacology; D003124:Colorimetry; D004305:Dose-Response Relationship, Drug; D005919:Glomerular Filtration Rate / Q000187:drug effects* / Q000502:physiology*; D066298:In Vitro Techniques; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism*; D008297:Male; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments / Q000494:pharmacology; D011863:Radioimmunoassay; D051381:Rats; D017208:Rats, Wistar; D012964:Sodium / Q000652:urine; D013373:Substance P / Q000031:analogs & derivatives / Q000494:pharmacology; D050916:TRPV Cation Channels / Q000819:agonists*
chemical_list: D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D064729:Neurokinin-1 Receptor Antagonists; D010446:Peptide Fragments; D050916:TRPV Cation Channels; C493922:Trpv1 protein, rat; C058636:calcitonin gene-related peptide (8-37); C065446:spantide II; D013373:Substance P; D012964:Sodium; D015740:Calcitonin Gene-Related Peptide; C071423:capsazepine; D002211:Capsaicin